Undisclosed Small Molecule Program

About Atengen

Atengen is pioneering a groundbreaking anti-angiogenic strategy that targets a specific receptor on tumor blood vessels to treat solid tumors. Founded in 2018 and based in Cambridge, MA, the company leverages a novel therapeutic target to develop both small molecule and antibody therapies intended to starve tumors by destroying their blood supply. This approach aims to be broadly applicable across many cancer types while minimizing resistance and off-target effects. The company is in the pre-clinical stage, supported by a world-class Scientific Advisory Board with deep expertise in oncology, angiogenesis, and drug development.

Therapeutic Areas

Other Solid Tumors (Pan-Cancer) Drugs